Sumatriptan Causes Parallel Decrease in Plasma Calcitonin Gene-Related Peptide (CGRP) Concentration and Migraine Headache During Nitroglycerin Induced Migraine Attack
- 1 March 2005
- journal article
- clinical trial
- Published by SAGE Publications in Cephalalgia
- Vol. 25 (3) , 179-183
- https://doi.org/10.1111/j.1468-2982.2005.00836.x
Abstract
Sumatriptan-induced changes in plasma calcitonin gene-related peptide (CGRP) concentration and headache intensity were investigated in 19 female migraineurs during nitroglycerin-induced migraine attack. Sumatriptan nasal spray was administered 120 min after the onset of the attack. Blood samples were obtained immediately before and 60 min after sumatriptan administration. In those subjects whose migraine attack improved considerably 60 min after the treatment the plasma CGRP concentration decreased significantly (P < 0.05). In contrast, plasma CGRP concentration failed to change in patients whose headache did not improve. In addition, plasma CGRP concentrations showed significant positive correlations with the headache scores both 60 and 120 min after sumatriptan administration (P < 0.05). According to our results plasma CGRP concentration decreases parallel to headache intensity during sumatriptan treatment and this decrease in CGRP predicts effectiveness of antimigraine drug therapy. This supports that one of the main effects of triptans is to decrease CGRP release.Keywords
This publication has 30 references indexed in Scilit:
- The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vesselsEuropean Journal of Pharmacology, 2002
- Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trialsThe Lancet, 2001
- 5-HT1B and 5-HT1D receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthaseBrain Research, 2001
- An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular systemPain, 2001
- The Pharmacodynamics of Sumatriptan in Nitroglycerin‐Induced HeadacheThe Journal of Clinical Pharmacology, 1999
- Sumatriptan Inhibits Neurogenic Vasodilation of Dural Blood Vessels in the Anaesthetized Rat—Intravital Microscope StudiesCephalalgia, 1997
- Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine modelJournal of Neuroscience Research, 1997
- The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnnals of Neurology, 1993
- Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglionNeuropharmacology, 1991
- Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptanThe Lancet, 1991